|Videos|December 6, 2021

Adverse pathology predicts metastasis, death in patients with prostate cancer

“Adverse pathology is a clear predictor of long-term outcomes for patients,” says Eric A. Klein, MD.

In this video, Eric A. Klein, MD, discusses the background and findings of the recent Urologic Oncology: Seminars and Original Investigations study, Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy, for which he served as senior author. Klein is the emeritus chair of the Cleveland Clinic Glickman Urological & Kidney Institute.


Related to this article

Rethinking Testosterone Therapy After the FDA Label Revisions
Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.